Santen Pharmaceutical Co Ltd (JP:4536)
:4536
Want to see JP:4536 full AI Analyst Report?
4536 Stock Chart & Stats
¥1597.00
-¥11.50(-0.71%)
At close: 4:00 PM EST
¥1597.00
-¥11.50(-0.71%)
Day’s Range― - ―
52-Week Range¥1,397.00 - ¥1,939.00
Previous CloseN/A
Volume1.29M
Average Volume (3M)1.30M
Market Cap
¥530.26B
Enterprise Value¥505.53B
Total Cash (Recent Filing)¥61.54B
Total Debt (Recent Filing)¥36.15B
Price to Earnings (P/E)16.7
Beta0.45
Next Earnings
May 12, 2026EPS Estimate
30.79Next Dividend Ex-DateN/A
Dividend Yield2.3%
Share Statistics
EPS (TTM)24.40
Shares Outstanding322,281,650
10 Day Avg. Volume1,416,570
30 Day Avg. Volume1,302,203
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)1.73
Price to Sales (P/S)1.65
P/FCF Ratio9.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)112.79
Revenue Forecast (FY)¥295.72B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetSanten's very low debt-to-equity (around 0.10–0.13) and large equity base provide durable financial flexibility. This conservative capital structure supports continued R&D and manufacturing investment, smooths funding for launches, and reduces refinancing risk over the next several months.
Profitability ReboundThe company returned to consistent profitability after 2023, with TTM net margin above 10%. This rebound indicates improved cost control and earnings power, strengthening the firm's ability to fund product lifecycle activities and sustain margins despite cyclical pressures.
Strong Cash ConversionFree cash flow that closely tracks net income (~85–89%) signals high earnings quality and reliable cash generation. That conversion supports reinvestment, dividend capacity, and strategic flexibility even if revenue growth is soft, sustaining operations over the medium term.
Bears Say
Declining RevenueRevenue has declined (roughly -4.6% in the provided metric) and the income statement notes softer top-line trends. Persistent revenue contraction can erode scale, reduce pricing power in regulated markets, and limit resources for new launches or geographic rollouts if not reversed.
Weakened Cash Flow MomentumOperating cash flow and free cash flow have stepped down in the TTM, suggesting higher working-capital needs or elevated investment spending. Reduced cash momentum raises execution risk for launches, lifecycle investments, and shareholder returns if weaker cash persists.
Shrinking Equity And AssetsA declining equity and asset base from 2022 levels narrows the balance-sheet cushion. That reduction limits borrowing capacity and financial flexibility to absorb further revenue weakness or fund opportunistic M&A and could force tougher trade-offs if headwinds continue.
Santen Pharmaceutical Co News
4536 FAQ
What was Santen Pharmaceutical Co Ltd’s price range in the past 12 months?
Santen Pharmaceutical Co Ltd lowest stock price was ¥1397.00 and its highest was ¥1939.00 in the past 12 months.
What is Santen Pharmaceutical Co Ltd’s market cap?
Santen Pharmaceutical Co Ltd’s market cap is ¥530.26B.
When is Santen Pharmaceutical Co Ltd’s upcoming earnings report date?
Santen Pharmaceutical Co Ltd’s upcoming earnings report date is May 12, 2026 which is in 13 days.
How were Santen Pharmaceutical Co Ltd’s earnings last quarter?
Santen Pharmaceutical Co Ltd released its earnings results on Feb 05, 2026. The company reported ¥24.4 earnings per share for the quarter, missing the consensus estimate of ¥29.293 by -¥4.893.
Is Santen Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Santen Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Santen Pharmaceutical Co Ltd pay dividends?
Santen Pharmaceutical Co Ltd pays a Semiannually dividend of ¥19 which represents an annual dividend yield of 2.3%. See more information on Santen Pharmaceutical Co Ltd dividends here
What is Santen Pharmaceutical Co Ltd’s EPS estimate?
Santen Pharmaceutical Co Ltd’s EPS estimate is 30.79.
How many shares outstanding does Santen Pharmaceutical Co Ltd have?
Santen Pharmaceutical Co Ltd has 322,281,650 shares outstanding.
What happened to Santen Pharmaceutical Co Ltd’s price movement after its last earnings report?
Santen Pharmaceutical Co Ltd reported an EPS of ¥24.4 in its last earnings report, missing expectations of ¥29.293. Following the earnings report the stock price went up 0.881%.
Which hedge fund is a major shareholder of Santen Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4536
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Santen Pharmaceutical Co Ltd
Santen Pharmaceutical Co., Ltd. (Ticker: 4536) is a global pharmaceutical company headquartered in Japan, specializing in the research, development, manufacturing, and marketing of products primarily for ophthalmology. Established in 1890, Santen focuses on innovative treatments for various eye diseases and conditions, including glaucoma, retinal disorders, and dry eye disease. The company operates in multiple sectors, including prescription pharmaceuticals, over-the-counter (OTC) products, and medical devices, aiming to improve the quality of life for patients worldwide.
Technical Analysis
Astellas Pharma
―
Menicon Co
―
Nipro
―
Tsubota Laboratory Incorporated
―
Japan Eyewear Holdings Co.,Ltd.
―
Options Prices
Currently, No data available
---